NeuroPace Asked To Submit Submission Issue Request By FDA For Its RNS System To Include Patients With Antiseizure Medication-Resistant Idiopathic Generalized Epilepsy; FDA Indicated PMA Supplment Not Approvable In Current Form

NeuroPace Raises FY2026 Sales Guidance from $99.000M-$101.000M to $99.500M-$101.500M vs $99.913M Est

NeuroPace (NASDAQ:NPCE) raises FY2026 sales outlook from $99.000 million-$101.000 million to $99.500 million-$101.500 million vs $99.913 million estimate.

NeuroPace Q2 EPS $(0.18) Beats $(0.20) Estimate, Sales $22.826M Beat $22.654M Estimate

NeuroPace (NASDAQ:NPCE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same

Neuropace shares are trading lower after the company announced it received communication from the FDA indicating that the PMA Supplement for idiopathic generalized epilepsy is not approvable in its current form.

Avis Budget Posts Weak Q2 Results, Joins Fiverr International, Costar Group And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session

US stock futures mixed, Dow up 0.1%. Avis Budget Group (CAR) shares down 13.3% after missing earnings & sales estimates. Other stocks also down.